Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
1. To compare evidence of preservation of joint structure after administration of CP-690,550 in doses of 5 mg BID and 10 mg BID versus MTX alone in MTX-naïve patients with active RA, as measured by changes from baseline using a standardized, validated method, such as the van der Heijde modified Sharp score at Month 6. 2. To compare the efficacy of CP-690,550 in doses of 5 mg BID and 10 mg BID versus MTX alone for the treatment of signs and symptoms of rheumatoid arthritis (RA) in MTX-naïve patients with active RA, as measured by ACR70 response rates at Month 6. 3. To evaluate the safety and tolerability of CP-690,550 in doses of 5 mg BID and 10 mg BID versus MTX alone in MTX-naïve patients with active RA for 24 months.
Inclusion criteria
- Moderate to severe active rheumatoid arthritis